Related Experiment Video
Updated: Apr 27, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
MicroRNA signature for HER2-positive breast and gastric cancer
Han Sung Kang1, Sang-Geun Jang1, Sun Young Kwon2
1National Cancer Center, Goyang, Republic of Korea.
Background/Aim:
The molecular mechanism for aggressive clinical behaviour related to v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) amplification is not fully-understood. In particular, little is known about microRNAs in the human epidermal growth factor receptor 2 (HER2) signaling network.
Patients And Methods:
Using microRNA microarray, the microRNA profiles of 16 HER2-positive breast carcinomas were compared with those of five luminal-type breast carcinomas. Additionally, two frozen, ERBB2-amplified gastric carcinomas were compared with their adjacent normal tissue samples. MicroRNAs that were differentially expressed according to the HER2 status in breast and gastric carcinomas were identified as the HER2 microRNA signature.
Results:
MiR-337 and miR-302f were commonly overexpressed in HER2-postive breast and gastric cancer. MiR-139 and miR-129 were commonly underexpressed in HER2-positive breast and gastric cancer. A concordant pattern of microRNA expression was noted between discovery sets and the majority of candidate microRNAs (two out of three) in three validation sets.
Conclusion:
Our study identified novel microRNAs that were differentially expressed according to the HER2 status across different tumor types.
Insights
This study identified novel microRNAs (miRNAs) associated with human epidermal growth factor receptor 2 (HER2) amplification in breast and gastric cancers. These findings advance understanding of HER2-driven tumor development and potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The molecular mechanisms driving aggressive ERBB2 (HER2) amplification remain unclear.
- Knowledge regarding microRNAs within the HER2 signaling network is limited.
Purpose of the Study:
- To identify differentially expressed microRNAs associated with HER2 status in various cancer types.
- To establish a HER2 microRNA signature across breast and gastric carcinomas.
Main Methods:
- MicroRNA microarray analysis was performed on HER2-positive and luminal breast carcinomas.
- ERBB2-amplified gastric carcinomas and adjacent normal tissues were analyzed.
- Differential microRNA expression was identified based on HER2 status.
Main Results:
- A distinct HER2 microRNA signature was identified in both breast and gastric cancers.
- MiR-337 and miR-302f were commonly overexpressed in HER2-positive tumors.
- MiR-139 and miR-129 were commonly underexpressed in HER2-positive tumors, with consistent patterns across validation sets.
Conclusions:
- Novel microRNAs differentially expressed in relation to HER2 status were identified.
- These findings contribute to understanding the role of microRNAs in HER2-driven oncogenesis.
- The identified microRNAs may represent potential biomarkers or therapeutic targets for HER2-amplified cancers.
More Related Videos
09:06MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs